Trinity Biotech Reaches Profitability Inflection Point, Marking Major Milestone in Strategic Turnaround
1. Trinity Biotech expects Adjusted EBITDA-positive operations from Q2 2025 onward. 2. Operational restructuring has significantly reduced costs, enabling profitability. 3. Revenue is projected to rise to $11-$12 million in Q2 2025. 4. The continuous glucose monitoring solution presents major growth potential. 5. World Health Organization approval boosts manufacturing reliability for HIV tests.